Clostridium Difficile Infection Treatment Market Global Industry Analysis and Growth By 2020 – Size, Share, Trends, Opportunities, Top 5 Key Players and Regional Forecast Up To 2026

Clostridium difficile infection refers to a symptomatic infection caused due to the spore-forming bacterium Clostridium difficile. Its symptoms include fever, watery diarrhea, nausea, and pain in stomach. Further complications may include toxic megacolon, pseudomembranous colitis, sepsis, and perforation of the colon. Generally, clostridium difficile infection occurs during antibiotic treatment or can be caused due to healthcare associated infection with clinical manifestation ranging from asymptomatic infection to watery diarrhea. This infection can be diagnosed by enzyme immunoassays for toxins or Clostridium difficile glutamate dehydrogenase (GDH) and nucleic acid amplification tests for Clostridium difficile toxin genes or endoscopy. Limited types of drugs such as metronidazole, fidoxamycin and vancomycin are only available for the treatment of Clostridium difficile infection. In case of any severe pain or toxic megacolon in abdominal wall, patients undergo surgery for removal of infected portion.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1492

High prevalence of this disease and occasional disease outbreaks in the emerging economies are expected to drive growth of Clostridium difficile infection treatment market. However, alternative therapy for broad spectrum antibiotic such as cephalosporins or fluoroquinolone will hinder the growth of Clostridium difficile infection treatment market.

The Global Clostridium Difficile Infection Treatment Market Taxonomy:

By Drug Class

Metronidazole

Fidoxamycin

Vancomycin

Other Drug Class

By Route of Administration

Oral

Intravenous / Parenteral

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Exclusive offer!!! Purchase the report at a discounted rate!!!

Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount

Quick Buy – Clostridium Difficile Infection Treatment Market Research Report: https://bit.ly/3cet96S

The Global Clostridium Difficile Infection Treatment Market Driver

Growing occurrence of Clostridium difficile infection is expected to drive growth of the global Clostridium difficile infection treatment market during the forecast period. Clostridium difficile infection is prevalent in geriatric population, people with weak immune system, people under long-term broad spectrum antibiotic, and people who have undergone intestinal surgery. According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile is the major cause of healthcare associated infection causing around 500,000 infection and 29,000 deaths per year in the U.S. The recent increase in incidences and severity of Clostridium difficile is subjected to increasing use of broad spectrum antibiotic such as cephalosporins, clindamycin, penicillin or fluoroquinolone and emergence of hypervirulent NAP1/BI/ribotype 027 strains, which are more resistant to present class of antibiotics. Furthermore, lack of compliance of hygiene norms in hospitals and uncontrolled use of broad spectrum antibiotic is increasing the rate of prevalence of this infection. All these factors are expected to drive growth of global Clostridium difficile infection treatment market.

Furthermore, rising incidence of Clostridium difficile infection has accelerated the demand for strengthening of research and development program, thereby propelling growth of the global Clostridium difficile infection treatment market. For instance, in 2017, Actelion conducted phase III clinical trial for comparing cadazolid with vancomycin for the treatment of Clostridium difficile associated diarrhea. Furthermore, in 2018, Rebiotix Inc., a clinical stage microbiome company initiated phase III trials for microbiota drug, RBX2660 for rehabilitation of microbial flora after Clostridium difficile infection and mechanism of restoration was demonstrated by using collaborator, CoreBiome’s BoosterShot technology. Moreover, Food and Drug Administration (FDA) designated RBX2660 as Breakthrough Therapy for its potential to prevent recurrent Clostridium difficile infection. In 2017, Finch and Crestovo merge aimed at development of microbiome pipeline for Clostridium difficile infection.

Moreover, development of better diagnostic tools is expected to support growth of global Clostridium difficile infection treatment market. For instance, Quidel introduced Solana, a FDA-approved molecular assay for qualitative Clostridium difficile infection detection. The company claims it as a quick and accurate diagnosis that can process 12 samples in one-shot in 35 min. Moreover, in 2017, Roche developed a Cobas Cdiff nucleic acid test for use on an automated Cobas Liat System, which uses a real time PCR for the detection of Clostridium difficile toxin B. Therefore, therapeutic and diagnostic advancements will enhance Clostridium difficile infection treatment market.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/clostridium-difficile-infection-treatment-market-1492

The Global Clostridium Difficile Infection Treatment Market – Regional Analysis

On the basis of region, the global Clostridium difficile infection treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Among regions, North America is expected to hold the dominant position in the global Clostridium difficile infection treatment market during the forecast period. This is owing to increasing prevalence of Clostridium difficile infection in this region. Furthermore, European economies are expected to face a decline in the global Clostridium difficile infection treatment market, owing to mandatory surveillance, monitoring of antibiotic prescriptions, and reformed compliance with isolation, hand washing, and hygiene protocols. The statistics revealed by Public Health England suggests that Clostridium difficile infection has substantially decreased from 55,498 cases to 13,361 cases between the period of 2007- 2008 and 2013 -2014. Asia pacific is the largest market region due to poor healthcare infrastructure and facilities, and lack of hygiene conditions.

The Global Clostridium Difficile Infection Treatment Market – Competitors

The major players operating in the global Clostridium difficile infection treatment market include Merck & Co., Inc., Baxter International Inc., Sanofi S.A., Pfizer limited, Novartis, Astellas Pharma Inc., Eli Lilly and Company, AstraZeneca Plc., Actelion Pharmaceuticals Ltd (Sub. of Johnson & Johnson Services, Inc.), and Mylan N.V.

Table of Content

Global Clostridium Difficile Infection Treatment Market Research Report
Section 1: Global Clostridium Difficile Infection Treatment Industry Overview
Section 2: Global Economic Impact on Clostridium Difficile Infection Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Clostridium Difficile Infection Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Clostridium Difficile Infection Treatment Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837